BRIEF published on 07/08/2025 at 08:05, 1 year 2 months ago TME Pharma Terminates Liquidity Contract Amid Cost Optimization Liquidity Contract Biotechnology Refinancing Cost Optimization TME Pharma
PRESS RELEASE published on 07/08/2025 at 08:00, 1 year 2 months ago Informations privilégiées / Autres communiqués TME Pharma annonce la résiliation du contrat de liquidité avec Invest Securities pour optimiser ses coûts et renforcer sa trésorerie. Réduction des coûts opérationnels suite à la restructuration organisationnelle Contrat De Liquidité Optimisation Des Coûts TME Pharma Restructuration Organisationnelle Développement Thérapies
PRESS RELEASE published on 07/08/2025 at 08:00, 1 year 2 months ago Inside Information / Other news releases TME Pharma terminates liquidity contract with Invest Securities to optimize costs. Improve trading volume of shares and healthy liquidity deemed contract unnecessary. Finds success in refinancing and reducing operational costs Liquidity Contract Cost Optimization Trading Volume Organizational Restructuring TME Pharma
BRIEF published on 05/21/2025 at 08:05, 1 year 4 months ago TME Pharma Enhances Financial Outlook with €1.7M Bond Commitments Strategic Partnerships Bond Issuance Clinical Programs Financial Visibility Cost Structure
BRIEF published on 05/21/2025 at 08:05, 1 year 4 months ago TME Pharma améliore ses perspectives financières avec un engagement obligataire de 1,7 million d'euros Partenariats Stratégiques Emission D'obligations Programmes Cliniques Visibilité Financière Structure Des Coûts
PRESS RELEASE published on 05/21/2025 at 08:00, 1 year 4 months ago Inside Information / Other news releases TME Pharma extends financial visibility to May 2026 by securing €1.7M financing through regular bonds with attached warrants. CEO and board show strong commitment to company's success Clinical Programs TME Pharma Financial Visibility Regular Bonds Private Warrants
PRESS RELEASE published on 05/21/2025 at 08:00, 1 year 4 months ago Informations privilégiées / Autres communiqués TME Pharma, société de biotechnologie spécialisée en thérapies contre le cancer, prolonge sa visibilité financière jusqu'en mai 2026 via une émission d'obligations aux investisseurs professionnels Investisseurs Obligations Cancer Visibilité Financière TME Pharma
BRIEF published on 04/10/2025 at 19:05, 1 year 5 months ago TME Pharma strengthens its liquidity contract with Invest Securities Liquidity Contract Oncology INVEST SECURITIES Financial Markets TME Pharma
BRIEF published on 04/10/2025 at 19:05, 1 year 5 months ago TME Pharma renforce son contrat de liquidité avec Invest Securities Contrat De Liquidité INVEST SECURITIES Marchés Financiers Oncologie TME Pharma
PRESS RELEASE published on 04/10/2025 at 19:00, 1 year 5 months ago Inside Information / Other news releases TME Pharma increases resources for liquidity contract with Invest Securities by €5,000 to support cash balance and securities. Details of shares and cash balance provided Liquidity Contract INVEST SECURITIES Clinical-stage Biotechnology Resources TME Pharma
Published on 09/30/2026 at 15:50, 1 hour 14 minutes ago Innodata Opens Motion-Capture AI Lab to Help Humanoids Move Like Humans
Published on 09/30/2026 at 14:37, 2 hours 27 minutes ago NuRAN Leverages Starlink Backhaul to Drive Higher Revenue Per Rural Site
Published on 09/30/2026 at 14:31, 2 hours 33 minutes ago First Breach Expands Ammunition Manufacturing Operations to Seven Days a Week
Published on 09/30/2026 at 14:07, 2 hours 57 minutes ago Worksport COR Energy System Now Available Through Amazon
Published on 09/30/2026 at 13:30, 3 hours 34 minutes ago Nextech3D.ai Engages MZ Group to Lead Strategic Investor Relations Program
Published on 09/30/2026 at 16:32, 31 minutes ago VVV Sports Limited: Interim Results for the six months ended 30 June 2026
Published on 09/30/2026 at 16:30, 34 minutes ago Original-Research: HORNBACH Holding AG & Co. KGaA (von Quirin Privatbank Kapitalmarktgeschäft): Buy
Published on 09/30/2026 at 16:20, 44 minutes ago EQS-Adhoc: MS Industrie AG: MS XTEC acquires a 51% majority stake in IDAS d.o.o., Mol, Serbia
Published on 09/30/2026 at 16:00, 1 hour 4 minutes ago Piramal Pharma Solutions and NP2 to Complete Cyclophosphamide Development Phase Next Month
Published on 09/30/2026 at 15:41, 1 hour 23 minutes ago Branicks Group AG 2026 Half-Year Report: Steady Operational Progress, Key Structural Changes Implemented
Published on 09/30/2026 at 12:14, 4 hours 50 minutes ago Mise à disposition du rapport financier semestriel au 30 juin 2026
Published on 09/30/2026 at 12:00, 5 hours 4 minutes ago Kapitaalverhoging door uitoefening van inschrijvingsrechten
Published on 09/30/2026 at 12:00, 5 hours 4 minutes ago Capital increase through exercise of subscription rights
Published on 09/30/2026 at 08:45, 8 hours 19 minutes ago Air Liquide invests over 170 million euros to support a semiconductor leader expanding manufacturing capabilities in Japan
Published on 09/30/2026 at 08:45, 8 hours 19 minutes ago Air Liquide investit plus de 170 millions d’euros pour accompagner un leader des semi-conducteurs dans le développement de ses capacités de production au Japon
